肾素-血管紧张素系统抑制剂用于无心力衰竭的稳定性冠心病患者:随机试验的系统评价与Meta分析
该系统评价与Meta分析纳入24项随机试验、随访198 275患者年,比较RASi与安慰剂或活性对照在无心力衰竭(左室射血分数≥40%或无临床心衰)的稳定性冠心病患者中的疗效。与安慰剂相比,RASi降低全因死亡(率比0.84,95%CI 0.72-0.98)、心血管死亡(0.74,0.59-0.94)、心肌梗死(0.82,0.76-0.88)、卒中(0.79,0.70-0.89)及心绞痛、心力衰竭、血运重建;但与活性对照相比无显著差异(全因死亡1.05,0.94-1.17;交互作用P=0.006)。贝叶斯Meta回归显示,RASi对全因和心血管死亡的获益仅见于对照事件率高的试验(>14.10例死亡和>7.65例心血管死亡/1000患者年)。结论:证据不支持RASi优先于其他活性对照。
要点
- 与安慰剂相比,RASi降低无心力衰竭稳定性冠心病患者的全因死亡(率比0.84,95%CI 0.72-0.98)和心血管死亡(0.74,0.59-0.94)。
- 与活性对照相比,RASi对全因死亡(1.05,0.94-1.17;交互作用P=0.006)和心血管死亡(1.08,0.93-1.25;交互作用P<0.001)无显著获益。
- RASi与安慰剂相比降低心肌梗死(0.82,0.76-0.88)和卒中(0.79,0.70-0.89),但与活性对照相比无显著差异(心肌梗死0.99,0.87-1.12;交互作用P=0.01;卒中1.10,0.93-1.31;交互作用P=0.002)。
- 贝叶斯Meta回归显示,RASi与安慰剂相比对全因和心血管死亡的获益仅见于对照事件率高的试验(>14.10例死亡和>7.65例心血管死亡/1000患者年),低事件率试验中未见获益。
- 证据不支持RASi优先于其他活性对照用于无心力衰竭的稳定性冠心病患者。
适用人群与场景
- 无心力衰竭的稳定性冠心病患者,心力衰竭定义为左室射血分数≥40%或无临床心力衰竭。
- 纳入试验须至少入选100例无心力衰竭的冠心病患者,随访至少1年。
- 排除与血管紧张素转换酶抑制剂比较血管紧张素受体阻滞剂的研究,以及被撤回或经涂改的研究。
研究设计与关键结果
- 研究设计:随机试验的系统评价与Meta分析,检索PubMed、EMBASE和CENTRAL数据库至2016年5月1日。
- 纳入24项随机试验,随访198 275患者年。
- 与安慰剂相比,RASi降低全因死亡(率比0.84,95%CI 0.72-0.98)、心血管死亡(0.74,0.59-0.94)、心肌梗死(0.82,0.76-0.88)、卒中(0.79,0.70-0.89),以及心绞痛、心力衰竭和血运重建。
- 与活性对照相比,RASi对全因死亡(1.05,0.94-1.17;交互作用P=0.006)、心血管死亡(1.08,0.93-1.25;交互作用P<0.001)、心肌梗死(0.99,0.87-1.12;交互作用P=0.01)、卒中(1.10,0.93-1.31;交互作用P=0.002)无显著差异。
- 贝叶斯Meta回归分析显示,RASi与安慰剂相比对全因死亡和心血管死亡的效应取决于对照事件率,仅在高对照事件率试验(>14.10例死亡和>7.65例心血管死亡/1000患者年)中有获益,低对照事件率试验中无获益。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在无心力衰竭的稳定性冠心病患者中,RASi与安慰剂相比降低死亡和心血管事件,但证据不支持RASi优先于其他活性对照。
- RASi与安慰剂相比的获益主要见于对照事件率高的试验(>14.10例死亡和>7.65例心血管死亡/1000患者年),低事件率试验中未见获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To critically evaluate the efficacy of renin angiotensin system inhibitors (RASi) in patients with coronary artery disease without heart failure, compared with active controls or placebo.
DESIGN: Meta-analysis of randomized trials.
DATA SOURCES: PubMed, EMBASE, and CENTRAL databases until 1 May 2016.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomized trials of RASi versus placebo or active controls in patients with stable coronary artery disease without heart failure (defined as left ventricular ejection fraction ≥40% or without clinical heart failure). Each trial had to enroll at least 100 patients with coronary artery disease without heart failure, with at least one year's follow-up. Studies were excluded if they were redacted or compared use of angiotensin converting enzyme inhibitors with angiotensin receptor blockers. Outcomes were death, cardiovascular death, myocardial infarction, angina, stroke, heart failure, revascularization, incident diabetes, and drug withdrawal due to adverse effects.
RESULTS: 24 trials with 198 275 patient years of follow-up were included. RASi reduced the risk of all cause mortality (rate ratio 0.84, 95% confidence interval 0.72 to 0.98), cardiovascular mortality (0.74, 0.59 to 0.94), myocardial infarction (0.82, 0.76 to 0.88), stroke (0.79, 0.70 to 0.89), angina, heart failure, and revascularization when compared with placebo but not when compared with active controls (all cause mortality, 1.05, 0.94 to 1.17; Pinteraction=0.006; cardiovascular mortality, 1.08, 0.93 to 1.25, Pinteraction<0.001; myocardial infarction, 0.99, 0.87 to 1.12, Pinteraction=0.01; stroke, 1.10, 0.93 to 1.31; Pinteraction=0.002). Bayesian meta-regression analysis showed that the effect of RASi when compared with placebo on all cause mortality and cardiovascular mortality was dependent on the control event rate, such that RASi was only beneficial in trials with high control event rates (>14.10 deaths and >7.65 cardiovascular deaths per 1000 patient years) but not in those with low control event rates.
CONCLUSIONS: In patients with stable coronary artery disease without heart failure, RASi reduced cardiovascular events and death only when compared with placebo but not when compared with active controls. Even among placebo controlled trials in this study, the benefit of RASi was mainly seen in trials with higher control event rates but not in those with lower control event rates. Evidence does not support a preferred status of RASi over other active controls.
参考来源
- Bangalore S, Fakheri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017. PMID: 28104622. doi:10.1136/bmj.j4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。